StockWatch
·
Q2 FY-2027 RESULTS · PPLPHARMA

Piramal Pharma turns profitable; consolidated PAT ₹5.6 Cr as OPM expands to 13.3%

PAT +105.62% YoY · revenue +28.06% · margins expanding

Q2 FY27 resultsPPLPHARMAPiramal Pharma Ltd27 Oct 2026 · 3 min read
Revenue

₹2,617.06 Cr

+28.06% YoY

PAT (consolidated)

₹5.58 Cr

+105.62% YoY

Net margin

0.21%

+4.9pp YoY

EPS

₹0.04

Piramal Pharma's consolidated revenue rose 28.1% YoY (₹2,617.1 Cr vs ₹2,043.7 Cr) and 15.3% QoQ (vs ₹2,269.9 Cr), and the company returned to profit after two straight quarterly losses — consolidated PAT attributable to owners was ₹5.6 Cr versus losses of ₹99.2 Cr a year ago and ₹69.4 Cr last quarter. No exceptional items were booked this quarter (unlike FY26's ₹196.1 Cr full-year exceptional charge), so the swing is entirely operational rather than one-off-driven.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹2,617.06 Cr+15.3%+28.1%
Expenses₹2,589.1 Cr+8.5%+19.3%
PAT₹5.58 Cr+108.04%+105.62%
Net margin0.21%+3.1pp+4.9pp
EPS₹0.04-92.3%-94.7%

The turnaround was margin-led: consolidated OPM (EBITDA/revenue) expanded to 13.3% from 7.8% a year ago and 8.6% last quarter — a roughly 557bps YoY gain — as operating leverage kicked in on the higher revenue base. Net margin, however, stayed wafer-thin at 0.21%, since finance costs (₹87.6 Cr) and depreciation/amortisation (₹233.2 Cr) — both elevated by the ongoing Lexington sterile-injectable buildout — continue to absorb most of the operating gain. Standalone PAT, by contrast, came in at ₹170.7 Cr on standalone revenue of ₹1,345.4 Cr; the wide gap versus the ₹5.6 Cr consolidated figure reflects that overseas subsidiaries, which carry the bulk of the group's debt, D&A and the newly consolidated minority interest, are still near breakeven even as the India entity is comfortably profitable — readers should treat the consolidated number as the primary read.

₹
175.83189.89203.95218232.06198.7207-2408-1709-0810-0110-27Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹198.72, down 4.5% over the past month of trading.

₹ Cr
-153.14-94.77-36.3921.98-81.7Q1 FY26rev ₹1,934 Cr-99.22Q2 FY26rev ₹2,044 Cr-136.19Q3 FY26rev ₹2,140 Cr-8.82Q4 FY26rev ₹2,752 Cr-69.39Q1 FY27rev ₹2,270 Cr5.03Q2 FY27rev ₹2,617 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records.

What management guided (1 FY-2027 call)
Maintained FY27 guidance across CDMO and CHG despite Q1 outperformance; targeting 25% EBITDA margin by FY30 via operating leverage and differentiated offerings; capex USD120–135M annually; Lexington sterile-injectable expansion on track for CY2027 close.

— This quarter: beat

Revenue growth of 28% YoY runs well ahead of management's maintained FY27 guidance of mid-teen revenue growth from the Q1 call, and the OPM trajectory is consistent with the stated path to a 25% EBITDA margin by FY30. No Q2-specific brokerage consensus was found ahead of this print; full-year FY27 PAT estimates from Choice Equity Broking (~₹140 Cr) and Motilal Oswal (~₹110 Cr, adjusted) imply H2 needs to deliver roughly ₹175–205 Cr given H1FY27's cumulative owners' loss of ₹63.8 Cr — a step-up not yet evidenced on a single quarterly print. During the quarter PPL completed the acquisition of an incremental 40.67% stake in Yapan Bio, a Hyderabad CDMO, for ₹76.1 Cr, taking its holding to 74% and triggering first-time NCI consolidation (provisional goodwill, pending final purchase-price allocation); the company also flagged the Bayer distribution deal ending in 2026 and clarified that funding tied to its Ontario site is not material, though neither carries a quantified P&L impact in this filing. No standalone press release accompanied the filing to cross-check management's own framing of the quarter.

  • W1

    Whether OPM (13.3% this quarter) holds or extends further toward management's 25%-by-FY30 target in Q3

  • W2

    H2FY27 PAT trajectory needed to reach full-year analyst estimates of ₹110–140 Cr after a ₹63.8 Cr H1 loss

  • W3

    Lexington sterile-injectable expansion progress toward its guided CY2027 close, and its effect on the finance costs/D&A currently capping NPM at 0.21%

Informational and educational content only. Not investment advice.